Heart Rate Control With Esmolol in Septic Shock
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is investigate the effects on systemic hemodynamics and organ function of esmolol when used to maintain heart rate below a predefined threshold in patients with septic shock.
| Condition | Intervention | Phase |
|---|---|---|
|
Septic Shock |
Drug: esmolol Other: control |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Strict Heart Rate Control With Esmolol in Septic Shock: a Randomized, Controlled, Clinical Pilot Study |
- heart rate [ Time Frame: over a period of 96 hrs ] [ Designated as safety issue: No ]
- systemic hemodynamics [ Time Frame: over a period of 96 hours ] [ Designated as safety issue: No ]systemic hemodynamics,norepinephrine requirements,organ functions,adverse effects.
- ICU Mortality [ Time Frame: 28 days ] [ Designated as safety issue: No ]
| Enrollment: | 154 |
| Study Start Date: | December 2010 |
| Study Completion Date: | July 2012 |
| Primary Completion Date: | July 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: esmolol |
Drug: esmolol
Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm.
|
| control |
Other: control
standard treatment without strict heart rate control
|
Detailed Description:
154 septic shock patients with heart rate > of 95 bpm and requiring vasopressor support to maintain mean arterial pressure between 65 and 75 mmHg despite adequate volume resuscitation, will be enrolled in the study. Patients will be randomly allocated to be treated with either a) a continuous esmolol infusion at any doses to maintain heart rate between 95 and 80 bpm b)to a standard treatment without heart rate control(control; each n = 77). In both groups, norepinephrine will be titrated to achieve a mean arterial pressure (MAP) between 65 and 75 mmHg. Data from right heart catheterization,data from organ function as well as norepinephrine requirements will be obtained at baseline and after 24, 48, 72, and 96 hours. The protocol will require that esmolol be infused continuously at any doses to maintain the predefined heart rate threshold until one the following events occur: the patient die, a serious adverse effect attributed to the study drug infusion, or the patient has been discharged from ICU.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- septic shock criteria
- presence of heart rate > 95 bpm.
Exclusion Criteria:
- Pregnancy
- age < 18
Contacts and Locations| Italy | |
| Department of Anesthesiology and Intensive care of the University of Rome La Sapienza | |
| Rome, Italy | |
| Principal Investigator: | Andrea Morelli, MD | University of Roma La Sapienza |
More Information
No publications provided
| Responsible Party: | Andrea Morelli, MD, University of Roma La Sapienza |
| ClinicalTrials.gov Identifier: | NCT01231698 History of Changes |
| Other Study ID Numbers: | 2048 |
| Study First Received: | October 29, 2010 |
| Last Updated: | January 23, 2013 |
| Health Authority: | Italy: Ethics Committee |
Keywords provided by University of Roma La Sapienza:
|
septic shock esmolol tachycardia betablockers |
Additional relevant MeSH terms:
|
Shock Shock, Septic Pathologic Processes Sepsis Infection Systemic Inflammatory Response Syndrome Inflammation Esmolol |
Adrenergic beta-1 Receptor Antagonists Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 19, 2013